Equities analysts forecast that Vaccinex Inc (NASDAQ:VCNX) will announce ($0.53) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vaccinex’s earnings. Vaccinex posted earnings of ($0.93) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 43%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 12th.
On average, analysts expect that Vaccinex will report full year earnings of ($2.60) per share for the current fiscal year, with EPS estimates ranging from ($2.65) to ($2.54). For the next fiscal year, analysts forecast that the business will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.35) to ($1.73). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that cover Vaccinex.
Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.07). Vaccinex had a negative return on equity of 306.27% and a negative net margin of 6,349.13%. The business had revenue of $0.03 million for the quarter.
In other news, insider Maurice Zauderer bought 183,824 shares of the stock in a transaction dated Tuesday, July 30th. The stock was bought at an average price of $4.08 per share, for a total transaction of $750,001.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Albert Friedberg bought 1,838,235 shares of the stock in a transaction dated Tuesday, July 30th. The stock was purchased at an average price of $4.08 per share, with a total value of $7,499,998.80. The disclosure for this purchase can be found here. In the last quarter, insiders bought 4,701,682 shares of company stock valued at $83,254,186. 69.90% of the stock is currently owned by corporate insiders.
An institutional investor recently bought a new position in Vaccinex stock. Creative Planning acquired a new position in shares of Vaccinex Inc (NASDAQ:VCNX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $55,000. Creative Planning owned about 0.09% of Vaccinex as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.30% of the company’s stock.
VCNX opened at $6.07 on Thursday. The company’s fifty day moving average price is $5.30 and its two-hundred day moving average price is $5.53. Vaccinex has a 1-year low of $3.32 and a 1-year high of $10.05.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.